Amag Pharmaceuticals Inc., formerly known as Advanced Magnetics Inc., develops and markets superparamagnetic iron oxide nanoparticles used in pharmaceutical products. The company is dedicated to the development and commercialization of its proprietary nanoparticle technology for use in therapeutic iron compounds to treat anemia, as well as imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The company has two approved products, Feridex IV and GastroMARK, which are marketed primarily in the U.S. and Europe. Feridex IV is a liver contrast agent, and GastroMARK is an oral contrast agent used for delineating the bowel in MRI. The company has two primary product candidates, Ferumoxytol and Combidex. Ferumoxytol is in phase III multi-center clinical trials for use as an iron replacement therapeutic in chronic kidney disease patients, whether or not on dialysis. Combidex is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging (MRI) to aid in the differentiation of cancerous from normal lymph nodes.
Amag Pharmaceuticals was incorporated in Delaware in 1981 and is based in Cambridge, Massachusetts.